HM Payson & Co. lowered its stake in Becton Dickinson and Co (NYSE:BDX) by 9.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,605 shares of the medical instruments supplier’s stock after selling 7,011 shares during the period. HM Payson & Co.’s holdings in Becton Dickinson and were worth $17,123,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Becton Dickinson and by 1.3% during the third quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after purchasing an additional 283,433 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Becton Dickinson and by 1.3% during the third quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock worth $4,966,582,000 after purchasing an additional 253,041 shares during the last quarter. FMR LLC raised its holdings in shares of Becton Dickinson and by 8.0% during the third quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after purchasing an additional 1,286,579 shares during the last quarter. Fundsmith Equity Fund L.P. purchased a new position in shares of Becton Dickinson and during the second quarter worth $894,775,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Becton Dickinson and by 0.8% during the third quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock worth $930,491,000 after purchasing an additional 27,188 shares during the last quarter. 86.25% of the stock is owned by institutional investors and hedge funds.
BDX has been the subject of several recent research reports. KeyCorp reissued a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Citigroup dropped their price target on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research report on Tuesday, November 13th. Barclays initiated coverage on shares of Becton Dickinson and in a research report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price target on the stock. Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Finally, Royal Bank of Canada restated a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $254.20.
In other news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the sale, the director now owns 93,688 shares in the company, valued at $22,210,614.16. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the business’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $245.83, for a total transaction of $511,326.40. Following the transaction, the senior vice president now owns 4,497 shares in the company, valued at $1,105,497.51. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,908 shares of company stock worth $18,085,616. Company insiders own 1.00% of the company’s stock.
Shares of NYSE BDX traded up $1.41 during trading on Friday, hitting $251.51. The company had a trading volume of 12,959 shares, compared to its average volume of 1,221,982. Becton Dickinson and Co has a fifty-two week low of $209.91 and a fifty-two week high of $265.87. The firm has a market cap of $66.97 billion, a price-to-earnings ratio of 22.91, a price-to-earnings-growth ratio of 1.72 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.03 and a debt-to-equity ratio of 0.90.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The business had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter last year, the business earned $2.40 earnings per share. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. Equities research analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be given a $0.77 dividend. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend is Friday, December 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.22%. Becton Dickinson and’s dividend payout ratio (DPR) is 27.25%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Put Option
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.